Download PDF

Other users also viewed these articles

Mesalazine dose modification based on faecal calprotectin levels in patients with ulcerative colitis in clinical remission Gisela Piñero; Míriam Mañosa; Margalida Calafat; Eva Vayreda; Fiorella Cañete; Maria Puig; Eugeni Domènech;
Gastroenterol Hepatol. 2024;47:612-9
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;
Gastroenterol Hepatol. 2024;47:522-52
Treat-to-target approach in the management of inflammatory Bowel disease Paulina Nuñez F; Uma Mahadevan; Rodrigo Quera; Constanza Bay; Patricio Ibañez;
Gastroenterol Hepatol. 2021;44:312-9